Skip to main content

Table 4 Response of HBeAg-negative patients to various doses and duration of PEG-IFN alfa-2a therapy analyzed according to endpoint

From: Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Dose/duration and endpoint EOT Time after end of treatment (years)
0.5 1 2 3 4 5
90 μg/48 week
ALT normalization 1/3 1/3 1/3 1/3 1/3 1/3 1/2
Low HBV (<4.3 log copies/mL) 2/3 1/3 0/3 1/3 1/3 1/3 1/2
180 μg/48 week
ALT normalization 1/2 2/2 2/2 0/2 0/2 0/2 0/2
Low HBV (<4.3 log copies/mL) 2/2 0/2 0/2 0/2 0/2 0/2 0/2
  1. EOT end of treatment